Abstract
Non-tuberculous mycobacteria (NTM) infections are increasingly being reported worldwide. They are a major concern for healthcare professionals for multiple reasons, ranging from the intrinsic resistance of NTM to most conventionally utilized antimicrobials to inharmonious diagnostic criteria utilized for evaluation of NTM-infected patients, leading to high morbidity. In this review, we highlight the paucity of drugs having potent anti-NTM activity amongst the new antimicrobials currently under various stages of development for anti-tubercular activity and issue a call for the establishment of a concerted dedicated drug discovery pipeline targeting NTM.
MeSH terms
-
Adamantane / analogs & derivatives
-
Adamantane / pharmacology
-
Aminopyridines / pharmacology
-
Anti-Bacterial Agents / pharmacology*
-
Azepines / pharmacology
-
Benzamides / pharmacology
-
Clinical Trials as Topic
-
Diarylquinolines / pharmacology
-
Drug Discovery*
-
Ethylenediamines / pharmacology
-
Fluoroquinolones / pharmacology
-
Humans
-
Minocycline / analogs & derivatives
-
Minocycline / pharmacology
-
Mycobacterium Infections, Nontuberculous / drug therapy
-
Nitroimidazoles / pharmacology
-
Nontuberculous Mycobacteria / drug effects*
-
Oxazoles / pharmacology
-
Piperazines / pharmacology
-
Spiro Compounds / pharmacology
-
Thiazines / pharmacology
-
Tigecycline
-
Uridine / analogs & derivatives
-
Uridine / pharmacology
Substances
-
2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one
-
7-(7-amino-7-methyl-5-azaspiro(2.4)heptan-5-yl)-6-fluoro-1-(2-fluoro-1-cyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
-
Aminopyridines
-
Anti-Bacterial Agents
-
Azepines
-
Benzamides
-
CPZEN-45
-
Diarylquinolines
-
Ethylenediamines
-
Fluoroquinolones
-
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine
-
Nitroimidazoles
-
OPC-67683
-
Oxazoles
-
Piperazines
-
SQ-641
-
Spiro Compounds
-
Thiazines
-
Tigecycline
-
bedaquiline
-
nitromide
-
macozinone
-
Minocycline
-
Adamantane
-
Uridine